RTCT raises hard questions about sponsor liability, blinding integrity, DSMB overlap, and AI accountability that the industry hasn’t yet resolved. Both sides of that ledger deserve honest consideration.
- Pharma's Digital Transformation: Where It's Really At
- How AI Is Changing Clinical Trial Design, Not Just Speed
- What Is Clinical Trials Day? Why Technology Helps Research Rise
- DiMe's Navigator: Why Teams Still Stall On Digital Endpoints
- Why Are Life Science Companies So Poorly Prepared For RIM's Future?
- Digital Endpoints Are Ready. Clinical Development Isn't
- Why Clinical Trial Data Cleaning Must Go Continuous (And How To Do It)
- What Clinical Analytics Solutions Are Shaping Clinical Research
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Statistics & Data Management Group Reaches New Heights Of Clinical Trial Efficiency
Explore how a contract research organization was able to migrate from paper-based processes to cost-effectively increase efficiency, safeguard data quality, and deliver exceptional service levels to sponsors.
-
Navigating The Complexities Of Publication Planning
In the dynamic landscape of the life sciences industry, Medical Affairs (MA) teams and accessible digital platforms are pivotal in navigating the complexities of medical publication planning.
-
How A Dedicated Medical Affairs Team Drives Site Engagement
See how improvements made to SIP have allowed for quick access to study documents and bulk actions for streamlined document management and enhanced user experience.
-
Drive Innovation In Clinical Trial Software: 3 Trends You Need To Watch
The clinical trial landscape is undergoing a transformative shift as technology increasingly shapes study design and execution. Explore three pivotal trends that are driving this evolution.
-
Calling All Assessment Authors: Do You Want To Share Your COA With Sponsors Across The Globe?
Explore how eCOAs will become an effective way to capture data remotely throughout the trial as sponsors shift to decentralized clinical trials.
-
Our Unified Platform Serves As eSource For COVID Treatment Trial
Signant Biotech optimized technology for an emerging biopharmaceutical's Phase 2 COVID treatment trial in critically ill patients, minimizing paper data risks and streamlining consent and data management across multiple sites and solutions.
-
Early-Stage Biotech's AI Advantage Is A Window That Closes
The "greenfield" advantage allows biotechs to build AI-native trials from the start, replacing manual data entry with automated workflows and structured human oversight for better data integrity.
-
The TMF Trifecta: Finding Balance In An Era Of Constant Change
In this article, discover TMF through the operational framework of people, process, and technology and how these factors affect stakeholders.
-
Gain The ePRO Advantage With Real-Time Data Collection
Discover how ePRO automatically incorporates eCOA data into a study, improving the depth, timeliness, and accuracy of patient-reported outcomes data in the following ways.
-
Why ePROs In Oncology Are Perfect For Capturing The Patient's Voice
Recently released FDA guidance showcases why electronic patient-reported outcomes (ePROs) are ideal for capturing the “voice” of the patient. See how ePRO eases oncology trials.
RECENT NEWSLETTERS
- 05.28.26 -- FDA's Elsa AI Shift, RTCT Rules, And RWE That Works
- 05.21.26 -- AI, HEOR, And Hidden Costs Reshaping Clinical Trials
- 05.14.26 -- AI, RWE, And The Systems Breaking Clinical Trials
- 05.07.26 -- How AI, ICH E6(R3) & RWD Are Reshaping Clinical Trials
- 05.02.26 -- Best Of April: AI In Clinical Trials — What Working